NOVEMBER 14, 2025
A Novel Gene Therapy for Bacillus Calmette-Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer
ADSTILADRIN®(nadofaragene firadenovec-vncg) is the first and only FDA-approved intravesical non-replicating gene therapy for high-risk Bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer. This monograph reviews the role of ADSTILADRIN in the evolving treatment landscape, its efficacy and safety profile, and practical considerations for implementation in clinical practice.
Download to read this article in PDF format:
A Novel Gene Therapy for Bacillus Calmette-Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer
This article is in PDF format and it requires Adobe Reader.
If you do not have Adobe Reader installed on your computer then please download and install from the link below.
Download Adobe Reader